Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA1A | P0DMV8 | 2/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.43 |
| ▸ | GAPDH | P04406 | 1/20 | 0.43 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4712011 | 0.87 | GAPDH (0.47) | HSPA1APTPN7GAPDHHSPA8 | |
| SCHEMBL4712075 | 0.86 | GAPDH (0.45) | HSPA1APTPN7GAPDHHSPA8 | |
| SCHEMBL4712642 | 0.86 | BRAF (0.34) | HSPA1APTPN7GAPDHHSPA8BRAF | |
| SCHEMBL4711682 | 0.84 | GAPDH (0.45) | HSPA1APTPN7GAPDHHSPA8 | |
| SCHEMBL4715692 | 0.84 | HSPA1A (0.45) | HSPA1APTPN7GAPDHHSPA8 | |
| SCHEMBL4710922 | 0.84 | GAPDH (0.45) | HSPA1APTPN7GAPDHHSPA8 | |
| SCHEMBL4712095 | 0.83 | HSPA1A (0.47) | HSPA1APTPN7GAPDHHSPA8 | |
| SCHEMBL4711422 | 0.82 | GAPDH (0.43) | HSPA1AGAPDHHSPA8PTGS2HCRTR2 | |
| SCHEMBL6823825 | 0.81 | GAPDH (0.46) | HSPA1APTPN7GAPDHHSPA8 | |
| SCHEMBL4712064 | 0.79 | GAPDH (0.42) | HSPA1APTPN7GAPDHHSPA8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412361-B1 | SUBSTITUTED 5,6,6A,11B-TETRAHYDRO-7-OXA-5-AZA-BENZO[C]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS | GRUENENTHAL GMBH (DE) | 2008-07-23 | — | — | EP | claimed |
| US-7199130-B2 | Substituted 5,6,6a, 11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds as NMDA-antagonists | GRUENENTHAL GMBH (DE) | 2007-04-03 | — | — | US | claimed |
| US-20040248889-A1 | Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds as NMDA-antagonists | GRUENENTHAL GMBH (DE) | 2004-12-09 | — | — | US | claimed |
| EP-1412361-B1 | SUBSTITUTED 5,6,6A,11B-TETRAHYDRO-7-OXA-5-AZA-BENZO[C]FLUORENE-6-CARBOXYLIC ACID DERIVATIVES SERVING AS NMDA ANTAGONISTS | GRUENENTHAL GMBH (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-7199130-B2 | Substituted 5,6,6a, 11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds as NMDA-antagonists | GRUENENTHAL GMBH (DE) | 2007-04-03 | — | — | US | disclosed |
| US-7199130-B2 | Substituted 5,6,6a, 11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds as NMDA-antagonists | GRUENENTHAL GMBH (DE) | 2007-04-03 | — | — | US | disclosed |
| US-7199130-B2 | Substituted 5,6,6a, 11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds as NMDA-antagonists | GRUENENTHAL GMBH (DE) | 2007-04-03 | — | — | US | disclosed |
| US-20040248889-A1 | Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds as NMDA-antagonists | GRUENENTHAL GMBH (DE) | 2004-12-09 | — | — | US | disclosed |
| WO-2004069840-A2 | PRODUCTION OF TETRAHYDROQUINOLINE BENZOFURANS | Grünenthal GmbH (DE) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248889-A1 | Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds as NMDA-antagonists | GRIN3A, GRIK5, GRIN2C | HSPA1A 3663/4885PTPN7 3384/4885GAPDH 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.